Juehua Zhu

Dr. Juehua Zhu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2016 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
DKDeyan Kong
Deyan Kong
JZJuehua Zhu
Juehua Zhu
QLQian Liu
Qian Liu
YJYongjun Jiang
Yongjun Jiang
LXLily Xu
Lily Xu
XLXinfeng Liu
Xinfeng Liu

3 February 2024 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
YWYue Wang
Yue Wang
XCXiuying Cai
Xiuying Cai
QFQi Fang
Qi Fang
JZJuehua Zhu
Juehua Zhu

24 November 2020 in BMC Neurology
Verified
Journal Article
Open access
PDF file
YWYaya Wu
Yaya Wu
Hui ChenHui Chen
Hui Chen
XLXueyun Liu
Xueyun Liu
XCXiuying Cai
Xiuying Cai
YKYan Kong
Yan Kong
TLTan Li
Tan Li
Background: A reliable scoring tool to detect the risk of intracerebral hemorrhage (ICH) after intravenous thrombolysis for ischemic stroke is warranted. The present study was designed to develop and validate a new nomogram for individualized prediction of the probability of hemorrhagic transformation (HT) in patients treated with intravenous (IV) recombinant tissue plasminogen activator (rt-PA). Methods: We enrolled patients who suffered from acute ischemic stroke (AIS) with IV rt-PA treatment in our emergency green channel between August 2016 and July 2018. The main outcome was defined as any type of intracerebral hemorrhage according to the European Cooperative Acute Stroke Study II (ECASS II). All patients were randomly divided into two cohorts: the primary cohort and the validation cohort. On the basis of multivariate logistic model, the predictive nomogram was generated. The performance of the nomogram was evaluated by Harrell’s concordance index (C-index) and calibration plot. Results: A total of 194 patients with complete data were enrolled, of whom 131 comprised the primary cohort and 63 comprised the validation cohort, with HT rate 12.2, 9.5% respectively. The score of chronic disease scale (CDS), the global burden of cerebral small vascular disease (CSVD), National Institutes of Health Stroke Scale (NIHSS) score ≥ 13, and onset-to-treatment time (OTT) ≥ 180 were detected important determinants of ICH and included to construct the nomogram. The nomogram derived from the primary cohort for HT had C- Statistics of 0.9562 and the calibration plot revealed generally fit in predicting the risk of HT. Furthermore, we made a comparison between our new nomogram and several other risk-assessed scales for HT with receiver operating characteristic (ROC) curve analysis, and the results showed the nomogram model gave an area under curve of 0.9562 (95%CI, 0.9221–0.9904, P < 0.01) greater than HAT (Hemorrhage After Thrombolysis), SEDAN (blood Sugar, Early infarct and hyper Dense cerebral artery sign on non-contrast computed tomography, Age, and NIHSS) and SPAN-100 (Stroke Prognostication using Age and NIHSS) scores. Conclusions: This proposed nomogram based on the score of CDS, the global burden of CSVD, NIHSS score ≥ 13, and OTT ≥ 180 gives rise to a more accurate and more comprehensive prediction for HT in patients with ischemic stroke receiving IV rt-PA treatment.

12 April 2023 in Frontiers in Endocrinology
Verified
Journal Article
Open access
YWYue Wang
Yue Wang
GJGuannan Jiang
Guannan Jiang
JZJie Zhang
Jie Zhang
JWJingfeng Wang
Jingfeng Wang
WYWanchun You
Wanchun You
JZJuehua Zhu
Juehua Zhu
Background and objectives: Intravenous recombinant tissue plasminogen activator (rtPA) thrombolysis is an effective treatment for acute ischemic stroke. Hyperglycemia is a major risk factor for the occurrence, development, and prognosis of ischemic stroke. This meta-analysis purposefully estimates the association between hyperglycemia and poor prognosis in acute ischemic stroke patients receiving intravenous rtPA thrombolytic therapy.Materials and methods: According to the predefined inclusion criteria, we searched PubMed, Web of Science, and Cochrane Library databases. The association of high blood glucose(>140mg/dl) with symptomatic intracranial hemorrhage (sICH), poor clinical outcome and mortality at 90 days post-rtPA thrombolysis was studied using both a common effects model and a random effects model. Odds ratios (ORs) were plotted on forest plots.Results: Of a total cohort of 2565 patients who received intravenous thrombolytic therapy, 721 had higher blood glucose. High glucose level significantly increased the odds of sICH (OR 1.80; 95% confidence interval(95%CI): 1.30- 2.50) and poor clinical outcome at 90 days (OR 1.82; 95%CI: 1.52-2.19), and all-cause mortality at 90 days (OR 2.51; 95%CI:1.65-3.82).Conclusions: In our meta-analysis, high blood glucose was significantly associated with sICH, poor clinical outcome and higher mortality at 90 days.

27 December 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
MLMing Luo
Ming Luo
ZQZhihua Qiu
Zhihua Qiu
XTXiangyue Tang
Xiangyue Tang
LWLi Wu
Li Wu
SLShaojun Li
Shaojun Li
YJYongjun Jiang
Yongjun Jiang

1 November 2019 in Experimental Neurology
Verified
Journal Article
Closed access
HLHao Li
Hao Li
JMJunwei Ma
Junwei Ma
QFQi Fang
Qi Fang
HLHaiying Li
Haiying Li
HSHaitao Shen
Haitao Shen
GCGang Chen
Gang Chen